Danielle Griffin

Title: The Innovative Contributions of Danielle Griffin

Introduction

Danielle Griffin is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of adeno-associated virus (AAV) antibodies. With a total of 2 patents, her work has the potential to impact various therapeutic applications.

Latest Patents

Danielle Griffin's latest patents include innovative research on adeno-associated virus antibodies and fragments thereof. The first patent focuses on an isolated anti-AAV antibody or an antigen-binding fragment capable of specifically binding to an epitope of the AAVrh74 capsid protein and its uses. The second patent also pertains to isolated anti-AAV antibodies and fragments, emphasizing their potential applications in therapeutic settings.

Career Highlights

Danielle Griffin is currently associated with Sarepta Therapeutics, Inc., where she continues to advance her research in the field of gene therapy. Her work is crucial in developing treatments for genetic disorders, showcasing her commitment to improving patient outcomes through innovative solutions.

Collaborations

Danielle collaborates with notable colleagues, including Sohrab Khan and Louise Rodino-Klapac. These partnerships enhance her research efforts and contribute to the advancement of biotechnology.

Conclusion

Danielle Griffin's contributions to the field of biotechnology through her patents and work at Sarepta Therapeutics, Inc. highlight her role as an influential inventor. Her research on adeno-associated virus antibodies is paving the way for future innovations in gene therapy.